Elaris FlexCo announced an exclusive global license agreement with Valneva (VALN) for technology related to Valneva’s Clostridioides difficile vaccine candidate, VLA84. Under the agreement, Elaris obtains an exclusive global license to Valneva’s antigen technology targeting Clostridioides difficile. Building on this technology, Elaris plans to advance a next-generation vaccine program incorporating additional proprietary components designed to broaden protective immune responses. The agreement strengthens Elaris’ intellectual property position and supports advancement of its lead vaccine program. Elaris plans to advance the program through IND-enabling development with the goal of initiating clinical studies around 2027.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- VALN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Valneva Sets March 18 Date to Release Full-Year 2025 Results
- Valneva Ramps Up Investor Outreach Ahead of Key Lyme Vaccine Data
- Valneva Posts Stable 2025 Revenue, Sets 2026 Outlook Ahead of Key Lyme Vaccine Data
- Valneva’s IXCHIQ Chikungunya Vaccine Faces New UK Use Restrictions but Retains Positive Benefit–Risk Profile